Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Kebuzone→

Kebuzone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
853-34-9
Molecular formula
C19H18N2O3
Molecular weight
322.4 g/mol
Drug class
Pyrazolidinedione non-steroidal anti-inflammatory drug (NSAID)phenylbutazone-related antirheumatic
Mechanism of action
A phenylbutazone-related pyrazolidinedione with anti-inflammatory and analgesic activity associated with inhibition of prostaglandin synthesis. Clinical pharmacology and safety information are limited compared with contemporary NSAIDs.
Indications / reported uses
  • Historical or limited-jurisdiction use as an anti-inflammatory and analgesic agent for rheumatic and musculoskeletal conditions; it is not a routine contemporary first-line NSAID.

Sources: https://www.ncbi.nlm.nih.gov/mesh/?term=C100280 · https://pubchem.ncbi.nlm.nih.gov/#query=kebuzone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Kebuzone Environmental Risk Assessment (ERA) (the Kebuzone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.